NDR White Paper Issue 23: Horses to Humans thymopentin has value
Levamisole and thymopentin, the link in treating ALS
NDR White Paper Issue 23: Horses to Humans thymopentin has value
NDR White Paper Issue 21: Peptide Array Technology Provides a Cornerstone for ALS Research
Bionox
NDR White Paper Issue 20: Can Elamipretide target mitochondrial dysfunction in ALS?
White Paper Issue 19: NDRs miRNA project
White Paper Issue 18: Bringing Patients to Treatments
White Paper Issue 17: Effectiveness of levamisole HCl and thymalfasin in two mouse models of ALS
White Paper Issue 16: Seeing ALS
White Paper Issue 15: Are in vitro Neuronal Cells Models for ALS discovery?
White Paper Issue 14: Utility to Futility: Zilucoplan fails in human ALS trial
White Paper Issue 13: NDR’s Roadmap to an ALS Cure
NDR White Paper Issue 11: Mechanisms of common pathologies in ALS
NDR White Paper Issue 10: Genetics and ALS
White Paper Issue 9: Stress Response in ALS: Dr. Robert Naviaux
NDR White Paper Issue 8: ALS and epigenetics
NDR White Paper Issue 7: Models of ALS
NDR White Paper Issue 6: Energy Metabolism
NDR White Paper Issue 5: Activity of Thymosan
NDR White Paper Issue 4: C9orf72
NDR White Paper Issue 3: Adipose & Secretome
NDR White Paper Issue 2: Treatments Are Lacking
NDR White Paper Issue 1: Thymopoietin